scispace - formally typeset
E

Elizabeth Hahn-Dantona

Researcher at Stony Brook University

Publications -  10
Citations -  1264

Elizabeth Hahn-Dantona is an academic researcher from Stony Brook University. The author has contributed to research in topics: Matrix metalloproteinase & Enzyme activator. The author has an hindex of 8, co-authored 10 publications receiving 1215 citations. Previous affiliations of Elizabeth Hahn-Dantona include Memorial Sloan Kettering Cancer Center & Scripps Research Institute.

Papers
More filters
Journal ArticleDOI

Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion

TL;DR: The activated MMP-9 enhances the invasive phenotype of the cultured cells as their ability to both degrade extracellular matrix and transverse basement membrane is significantly increased following zymogen activation.
Journal ArticleDOI

The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism.

TL;DR: It is demonstrated that LRP is a functional receptor for MMP-9 and suggested a major role for LRP in modulating remodeling of the extracellular matrix by regulatingextracellular proteinase activity.
Journal ArticleDOI

The Low Density Lipoprotein Receptor-related Protein LRP Is Regulated by Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Proteolysis in Malignant Cells

TL;DR: It is demonstrated that the presentation of LRP and the subsequent uptake of its ligands by malignant cells are both strongly regulated by MT1-MMP, a key protease in cell invasion and a physiological activator of MMP-2.
Journal ArticleDOI

Activation of ProMMP‐9 by a Plasmin/MMP‐3 Cascade in a Tumor Cell Model: Regulation by Tissue Inhibitors of Metalloproteinases

TL;DR: The activated MMP‐9 enhances the invasive phenotype of the cultured cells as their ability to transverse basement membrane is significantly increased following zymogen activation, and this enhanced tissue remodeling capability is demonstrated through the use of a specific anti‐M MP‐9‐blocking monoclonal antibody.